Clinical trials: Resistant Infection
Enterobacteriaceae Infections, Carbapenem-Resistant Enterobacteriaceae Infection
Aztreonam-Avibactam in Immunocompromised Hosts
The goal of this observational study is to learn about the effectiveness and safety of aztreonam-avibactam (ATM-AVI), an antibiotic used to treat infections caused by highly resistant bacteria, in adults with weakened immune…
- Conditions
- Enterobacteriaceae Infections, Carbapenem-Resistant Enterobacteriaceae Infection, Immunocompromised Host, Drug Resistance, Multiple, Bacterial
- Trial name
- IMMUNO-AVI (NCT07890480)
- Testing
- Aztreonam-Avibactam, Ceftazidime-Avibactam Plus Aztreonam
- Where
- Argentina
- Volunteers
- 814 people
- Sponsor
- Centro de Educación Medica e Investigaciones Clínicas Norberto Quirno
Bacteremia
IL-10 Stratifying Tool for Towards Antibiotic Selection for MRSaB
Patients with MRSaB have high therapeutic failure rates and mortality rates. Recent studies have shown that an elevated IL-10 level is an independent risk factor of mortality.
- Trial name
- NCT02660346
- Testing
- Daptomycin, Vancomycin, Ceftaroline
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- Sharp HealthCare
HELICOBACTER PYLORI INFECTIONS, Metabolic Syndrome
Eradication of Helicobacter Pylori Improves Metabolic Syndrome Through Modulation of Gut Microbiota.
The Role of Gut Microbiota in the Mechanism of Helicobacter pylori Eradication-Induced Amelioration of Metabolic Syndrome-Related Parameters Study Sponsor: Nanjing First Hospital Principal Investigator: Dr.
- Trial name
- NCT07306988
- Testing
- Vonoprazan-Amoxicillin Dual Therapy, Vonoprazan-Amoxicillin with Bifidobacterium tetravaccae, Vonoprazan-Amoxicillin with Berberine
- Where
- China
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Nanjing First Hospital, Nanjing Medical University
Patients at High Risk of Antibacterial Treatment Upon Admission
Impact of Prescription Quality, Infection Control and Antimicrobial Stewardship on Gut Microbiota Domination by Healthcare-Associated Pathogens
Extended-spectrum beta-lactamase producing Enterobacteriaceae (EPE), vancomycin-resistant enterococci (VRE) and Clostridium difficile have become a major threat to hospitalised patients worldwide.
- Trial name
- PILGRIM (NCT03765528)
- Where
- Germany
- Volunteers
- 1,500 people
- Sponsor
- University Hospital of Cologne
Helicobacter Pylori Infection
Helicobacter Pylori Eradication Rates of Bismuth-containing Quadruple Therapy vs Modified Quadruple Therapy in Korea
South Korea has the highest incidence of gastric cancer worldwide and Helicobacter pylori infection is still prevalent. Clarithromycin-containing triple therapy is still the primary therapy approved by the Korean government.
- Trial name
- NCT03665428
- Testing
- PAMB treatment (modified quadruple therapy), PBMT treatment (bismuth-containing quadruple therapy)
- Where
- South Korea
- Volunteers
- 233 people, healthy volunteers welcome
- Sponsor
- Chuncheon Sacred Heart Hospital
Tuberculosis, HIV
Evaluating the Pharmacokinetics, Safety, and Tolerability of Bedaquiline in Infants, Children, and Adolescents With Multidrug-Resistant Tuberculosis, Living With or Without HIV
P1108 was a Phase I/II, open-label, single-arm, exposure-controlled dose finding study of BDQ in infants, children, and adolescents living with and without HIV, with clinically diagnosed or bacteriologically confirmed…
- Trial name
- NCT02906007
- Testing
- Bedaquiline
- Where
- 4 sites in Haiti, South Africa
- Volunteers
- 54 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Multidrug-resistant Tuberculosis, Extensively Drug-resistant Tuberculosis
Drug Interaction Study Between Linezolid and Clarithromycin in Tuberculosis Patients
Future patients might benefit from a combination of linezolid (LIN) and clarithromycin (CLA) in the treatment of Multidrug-resistant and Extensively Drug-resistant Tuberculosis (MDR/XDR-TB) due to possible synergistic activity as…
- Trial name
- NCT01521364
- Testing
- Addition of different doses of clarithromycin.
- Where
- Netherlands
- Volunteers
- 7 people
- Sponsor
- University Medical Center Groningen
Pseudomonas Infections, Pseudomonas Aeruginosa
Antimicrobial Therapy for Difficult-to-treat Pseudomonas Aeruginosa
The primary objective of the ADDICT study is to assess and compare the clinical efficacy of available options for antimicrobial therapy (new beta-lactam/beta-lactamase inhibitor combination, cefiderocol or older agents such as…
- Conditions
- Pseudomonas Infections, Pseudomonas Aeruginosa, Prognosis, Drug Resistance, Multiple, Bacterial
- Trial name
- ADDICT (NCT06738771)
- Where
- 48 sites in France, Reunion
- Volunteers
- 600 people
- Sponsor
- Centre Hospitalier Régional d'Orléans
Uncomplicated Plasmodium Falciparum Malaria
Triple Artemisinin-based Combination Therapy for Delaying Drug Resistance Development - a Randomized Clinical Trial
Background: Artemisinin resistance has emerged in parts of Southeast Asia, and there are reports in Africa of reduced susceptibility of Plasmodium falciparum parasites against artemisinin-based combination therapy (ACT).
- Trial name
- 3ACT (NCT05764746)
- Testing
- Artemether-lumefantrine and Amodiaquine Drug Combination, Artemether-lumefantrine then Artesunate amodiaquine, Artemether-lumefantrine
- Where
- 2 sites in Tanzania
- Volunteers
- 384 people
- Sponsor
- Muhimbili University of Health and Allied Sciences
Tuberculosis, Non-Tuberculosis Mycobacteria
Sputum Pharmacokinetics of TB Drugs and Bacterial Drug Resistance
Background: Many people around the world get tuberculosis (TB) and non-tuberculous mycobacteria (NTM) infections. Sometimes medicine that treats these infections does not get to where the bacteria are in the lungs.
- Trial name
- NCT02534727
- Where
- 2 sites in United States, China
- Volunteers
- 215 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Sars-CoV2, Critical Illness
COVID-19 and ICU-acquired MDR Bacteria
This multicenter before-after study aimed to determine the impact of infection related to SARS-CoV-2 on the incidence of ICU-acquired multidrug resistant (MDR) bacteria.
- Trial name
- COVID-BMR (NCT04378842)
- Where
- 7 sites in France
- Volunteers
- 368 people
- Sponsor
- University Hospital, Lille
Pneumonia
Telithromycin, Treating Adult Outpatients With Mild to Moderate Community-acquired Pneumonia (CAP) in High Bacterial Resistance Areas
Demonstrate efficacy of telithromycin over single-agent oral antibiotics usually prescribed by local guidelines ("usual care") for treating adult outpatients with mild to moderate community-acquired pneumonia (CAP) in high…
- Trial name
- NCT00538018
- Testing
- Telithromycin
- Volunteers
- 978 people
- Sponsor
- Sanofi
Antibiotic, Healthcare Associated Infection
Evaluating Antibiotic Stewardship Assisted by Computer in the University Hospital of Nancy (MACABAO)
Antibiotic resistance is one of the most pressing health threats that mankind faces now and in the coming decades. Antibiotic resistance leads to longer hospital stays, higher medical costs and increased mortality.
- Trial name
- MACABAO (NCT04976829)
- Testing
- Antibiotic stewardship and healthcare-associated infections surveillance assisted by computer
- Volunteers
- 100,000 people
- Sponsor
- Central Hospital, Nancy, France
Plasmodium Falciparum Malaria
Artemisinin-resistant Malaria in Cambodia
Background: Artemisinin-based combination therapies (ACTs) are the first-line treatments for malaria. ACTs are highly effective, but malaria caused by the Plasmodium falciparum parasite is becoming resistant to some ACTs.
- Trial name
- NCT01736319
- Where
- Cambodia
- Volunteers
- 561 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Bacterial Infections
New Antibiotic to Treat Pediatric Patients With Infections Due to a Specific Bacteria (Vancomycin-Resistant Enterococcus)
This study will treat pediatric patients who have infections that are due to a specific bacteria (Vancomycin-Resistant Enterococcus)
- Trial name
- NCT00035854
- Testing
- Zyvox® / Linezolid
- Where
- 21 sites in United States
- Volunteers
- 13 people
- Sponsor
- Pfizer
Clostridioides Difficile Infection, Drug Resistance, Bacterial
Effect of Oral Microbiota on MDRO Decolonization
Randomized, placebo-controlled trial to evaluate the safety and efficacy of oral intestinal microbiota capsules for decolonizing multidrug-resistant organisms (MDROs) and Clostridioides difficile in patients requiring prolonged…
- Conditions
- Clostridioides Difficile Infection, Drug Resistance, Bacterial, Gastrointestinal Microbiome, Multidrug-resistant Colonization
- Trial name
- NCT07496502
- Testing
- Microbiota capsule
- Where
- Mexico
- Volunteers
- 42 people
- Sponsor
- Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Antibiotic Usage
Antibiotic Footprint Thailand - Pilot Questionnaire Study
Antimicrobial-resistant bacterial infection is an important cause of death in Thailand and in other countries worldwide. Increasing use of antibiotics in both animals and humans is one of the main drive that increase the…
- Trial name
- AFT PILOT (NCT03368768)
- Testing
- Obtain inform consent via questionnaire of Monkey Survey
- Where
- Thailand
- Volunteers
- 237 people
- Sponsor
- University of Oxford
Hepatitis C, Medication Adherence
Patient-Centered Models of HCV Care for People Who Inject Drugs
People who inject drugs (PWID) have higher rates of hepatitis C virus (HCV) than do other groups. Effective, safe new treatments called direct-acting antiviral agents (DAAs) have been developed recently.
- Trial name
- HERO (NCT02824640)
- Testing
- Patient Navigation, modified Directly Observed Therapy
- Where
- United States
- Volunteers
- 755 people
- Sponsor
- Prisma Health-Upstate
Infection Resistant to Multiple Drugs
Prospective Observational Pilot-study for the Evaluation of the Nephro- an Neurotoxicity in the Anti-infectious Therapy With Inhalative Colistin Therapy for Patients With Ventilator-associated Pneumonia (VAP)
Multi-Drug resistant pathogens (MDR) are reported worldwide with increasing incidence, especially in intensive care settings. One of the drugs which are effective against MDRs, is colistin (polymyxin E).
- Trial name
- LOKALE (NCT01894347)
- Testing
- TDM, Monitoring of Neuro-and Nephropathology
- Where
- Germany
- Volunteers
- 9 people
- Sponsor
- Charite University, Berlin, Germany
Herpes Simplex, HIV Infections
Treatment of Acyclovir-Resistant Mucocutaneous Herpes Simplex Disease in Patients With AIDS: Open Label Pilot Study of Topical Trifluridine
To determine the safety, effectiveness, and toxicity of topical (local) trifluridine in treating mucocutaneous (at the nasal, oral, vaginal, and anal openings) Herpes simplex virus ( HSV ) disease that has shown resistance to…
- Trial name
- NCT00000635
- Testing
- Trifluridine, Bacitracin zinc/Polymyxin B sulfate
- Where
- 8 sites in United States
- Volunteers
- 25 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.